Significant Accounting Policies (Details) (USD $)
|
3 Months Ended | 6 Months Ended | 0 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | 7 Months Ended | 6 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Oct. 31, 2012
GSK
Convertible notes guarantee obligation
Regulus
security
|
Jun. 30, 2013
Collaborations
item
|
Jun. 30, 2013
Collaborations
New development candidate
Minimum
|
Jun. 30, 2013
Collaborations
New development candidate
Maximum
|
Jun. 30, 2013
Collaborations
Phase 1
Minimum
|
Jun. 30, 2013
Collaborations
Phase 1
Maximum
|
Jun. 30, 2013
Collaborations
Phase 2
Minimum
|
Jun. 30, 2013
Collaborations
Phase 2
Maximum
|
Jun. 30, 2013
Collaborations
Phase 3
Minimum
|
Jun. 30, 2013
Collaborations
Phase 3
Maximum
|
Jun. 30, 2013
Collaborations
Regulatory milestones
Minimum
|
Jun. 30, 2013
Collaborations
Regulatory milestones
Maximum
|
Jun. 30, 2013
Collaborations
Commercialization milestones
|
Jun. 30, 2013
Collaborations
AstraZeneca
|
Dec. 31, 2012
Collaborations
AstraZeneca
item
|
Jun. 30, 2013
Collaborations
AstraZeneca
item
|
Jun. 30, 2013
Collaborations
AstraZeneca
|
Jun. 30, 2013
Collaborations
AstraZeneca
Maximum
item
|
Jun. 30, 2013
Collaborations
AstraZeneca
ISIS-AR
item
|
Jun. 30, 2013
Collaborations
Biogen Idec
|
Dec. 31, 2012
Collaborations
Biogen Idec
item
|
Jan. 31, 2012
Collaborations
Biogen Idec
Agreement entered into in January 2012
|
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in June 2012
|
Dec. 31, 2012
Collaborations
Biogen Idec
Agreement entered into in December 2012
item
|
Jan. 31, 2013
Collaborations
Genzyme Corporation
|
Mar. 31, 2013
Collaborations
Genzyme Corporation
|
|
Research and development revenue under collaborative agreements | ||||||||||||||||||||||||||||||
Number of targets | 5 | 3 | ||||||||||||||||||||||||||||
Upfront fee received | $ 6,000,000 | $ 25,000,000 | $ 31,000,000 | $ 29,000,000 | $ 12,000,000 | $ 30,000,000 | ||||||||||||||||||||||||
Number of drugs collaborative partner may license under the separate research program | 3 | |||||||||||||||||||||||||||||
Number of units of accounting | 4 | 1 | ||||||||||||||||||||||||||||
License revenue recognized | 477,000 | 200,000 | 1,916,000 | 1,618,000 | 2,200,000 | 9,300,000 | ||||||||||||||||||||||||
Upfront fee deferred | 19,500,000 | |||||||||||||||||||||||||||||
Assumed change in estimated selling price of ISIS-STAT3 (as a percent) | 10.00% | |||||||||||||||||||||||||||||
Percentage by which earned revenue from ISIS-STAT3 would change based on assumed change in estimated selling price | 7.00% | |||||||||||||||||||||||||||||
Amount by which earned revenue from ISIS-STAT3 would change based on assumed change in estimated selling price | 750,000 | |||||||||||||||||||||||||||||
Number of collaborative agreements | 3 | |||||||||||||||||||||||||||||
Number of convertible notes no longer guaranteed | 2 | |||||||||||||||||||||||||||||
Number of categories of milestone events | 3 | |||||||||||||||||||||||||||||
Number of stages of life-cycle of drugs | 3 | |||||||||||||||||||||||||||||
Completion period | 12 months | 18 months | 1 year | 2 years | 1 year | 3 years | 2 years | 4 years | ||||||||||||||||||||||
Time to prepare and submit regulatory filings | 6 months | 12 months | ||||||||||||||||||||||||||||
Time to obtain approval | 1 year | 2 years | ||||||||||||||||||||||||||||
Example of sales threshold as milestone event | 1,000,000,000 | |||||||||||||||||||||||||||||
Milestone payment recognized | $ 46,000,000 | $ 10,000,000 | $ 3,500,000 | $ 25,000,000 | $ 25,000,000 |